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Abstract: Patients with COPD are frequently prescribed inhaled corticosteroids (ICS); however, 
it is unclear whether the treatment with ICS might modify responses to inhaled bronchodilators. 
Two 6-month, randomized, placebo-controlled, double-blind, double-dummy, parallel-group 
studies of tiotropium 18 μg once daily, compared with salmeterol, 50 μg bid, had been conducted 
in patients with moderate-to-severe COPD. Efﬁ  cacy was assessed by spirometry, transition 
dyspnea index (TDI), St. George´s Respiratory Questionnaire (SGRQ), and exacerbations. Data 
from both studies were combined to form subgroups with regard to concurrent use of ICS. 796 
patients receiving ICS were separately analyzed from 390 patients not receiving ICS. Mean age 
was 64 years, and pre-bronchodilator FEV1 was 1.06 L (ICS group) and 1.13 L (non-ICS group). 
Both bronchodilators increased morning mean + SE pre-dose FEV1 compared with placebo (ICS 
groups: tiotropium 110 + 20 mL, salmeterol 80 + 20 mL; non-ICS groups: tiotropium 150 + 30 
mL, salmeterol 110 + 30 mL; p > 0.05 for tiotropium vs salmeterol). Improvements in TDI and 
SGRQ and frequency of exacerbations also tended to be more profound for tiotropium. Treat-
ment with tiotropium in patients with moderate-to-severe COPD was superior to salmeterol in 
lung function, irrespective of concurrent use of ICS.
Keywords: chronic obstructive pulmonary disease, inhaled corticosteroids, salmeterol, tiotro-
pium, ﬂ  uticasone
Introduction
Chronic obstructive pulmonary disease (COPD) is characterized by a chronic pro-
gressive deterioration in lung function and commonly results in dyspnea on activity, 
and impaired health status. In addition, periodic worsenings of the disease, referred 
to as exacerbations, occur with increasing frequency as the disease advances and are 
felt to adversely affect health status and to hasten the already accelerated decline 
in lung function seen in COPD patients (Seemungal et al 1998; Kanner et al 2001; 
Donaldson et al 2002). COPD guidelines currently advocate aggressive smoking 
cessation, certain non-pharmacologic management strategies such as exercise and 
pulmonary rehabilitation, and a stepped approach to pharmacotherapy. The latter 
includes initial treatment with short-acting bronchodilators, progressing to the addi-
tion of long-acting anticholinergic bronchodilators or long-acting beta2-adrenergic 
bronchodilators, or both, for patients with more advanced airway obstruction and 
persisting symptoms. 
In contrast to current asthma guidelines, where inhaled corticosteroids (ICS) 
are central to therapy of all patients with regular symptoms (GINA 1995), current 
COPD-guidelines are more cautious regarding the role of ICS, recommending their 
use only in symptomatic COPD patients with a documented spirometric or clinical 
response to ICS, or in those patients with an FEV1 <50% predicted and who suffer International Journal of COPD 2007:2(2)  158
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repeated exacerbations requiring antibiotics and/or therapy 
with oral corticosteroids (Pauwels 2001; O’Donnell et al 
2003; NICE 2004). Despite what guidelines recommend, 
ICS are commonly prescribed for patients with COPD, while 
the merits of this practice continue to be debated (Barnes 
2000; Calverley 2000; Suissa 2006). This empiric practice 
may have some justiﬁ  cation, as it has been demonstrated 
that withdrawal of ICS from patients with COPD is associ-
ated with an increase in exacerbation rates and worsening 
health status, as well as a deterioration in lung function and 
increased exertional breathlessness (O’Brien et al 2001; 
van der Valk et al 2002; Wouters et al 2005). A few studies 
(Paggiaro et al 1998; Weir et al 1999; Burge et al 2000; 
Lung Health Study Research Group 2000; Pauwels 2002) 
have suggested a beneﬁ  cial effect from ICS at reducing the 
number of COPD exacerbations for patients with advanced 
disease (FEV1 <50% predicted), and a meta-analysis of such 
trials reported a 30% reduction in COPD exacerbations 
with ICS (Alsaeedi et al 2002). However, other randomized 
clinical trials have not shown beneﬁ  t from ICS in COPD 
(Bourbeau et al 1998; Calverley et al 2003a; Szafranski et al 
2003). Recently, the methodology of statistical analysis 
used in many of these trials has been questioned (Suissa 
2006). According to this line of reasoning, conclusions 
concerning the effect of ICS on the frequency of COPD 
exacerbations should be considered ﬂ  awed whenever the 
overall rate of COPD exacerbations has been calculated 
by treating all patients equally and simply averaging indi-
vidual patient exacerbation rates. This so-called unweighted 
approach is overly sensitive to individual follow-up times 
which usually vary signiﬁ  cantly within a given trial, and 
can therefore lead to a biased estimate of exacerbation rate 
ratios (Suissa 2006). 
While long-acting beta2-adrenergics appear to be effective 
when added to inhaled steroids for many outcomes in patients 
with advanced COPD (Mahler et al 2002; Calverley et al 
2003a, b, 2007), there are no data yet available assessing the 
efﬁ  cacy of adding tiotropium, a long-acting anticholinergic 
inhaled bronchodilator for once-daily inhalation (Maesen 
et al 1995; Disse et al 1999; Littner et al 2000; Gross 2004) to 
ICS alone in COPD patients. At least in theory, if ICS could 
reduce airway inﬂ  ammation, peripheral mucus plugging and 
airway wall compliance might be expected to improve, lead-
ing to a greater response to bronchodilator therapy. Whether 
differential effects might also be observed between different 
classes of bronchodilators is also unknown.
Donohue et al reported results from a placebo-control-
led study over 6 months comparing tiotropium and the 
long-acting beta2-adrenergic, salmeterol, in patients with 
moderately advanced COPD (Donohue et al 2002, 2003). 
Tiotropium provided sustained and superior improvement 
in 12-hour lung function compared to salmeterol. When the 
data from this trial were combined with a similar 6-month 
trial in COPD patients for the analysis of patient-centred 
outcomes, additional beneﬁ  ts for tiotropium over salm-
eterol were indicated in symptoms, health status and the 
frequency of COPD exacerbations (Brusasco et al 2003). 
In these latter two studies, 66% of the patients enrolled had 
been prescribed ICS on a regular basis. The completion of 
these two placebo-controlled 6-month clinical studies has 
presented the opportunity to retrospectively analyze the 
relative efﬁ  cacy of tiotropium and salmeterol as a function 
of the concomitant use of ICS in patients with moderately 
advanced COPD.
Patients and methods
Study design
This is a retrospective analysis of the pooled results of 
two similar 6-months, randomized, double-blind, double-
dummy, placebo-controlled, parallel group studies of inhaled 
tiotropium bromide (18 μg once daily via the HandiHaler®) 
and salmeterol (50 μg twice daily via a CFC metered dose 
inhaler) in the treatment of patients with COPD (study codes 
205.130 and 205.137). The only difference in the two studies 
was the duration of serial spirometry in the clinic (12 hours 
in one study, 3 hours in the second) (Brusasco et al 2003; 
Donohue et al 2002, 2003). The studies were conducted in 
18 countries. All patients provided written consent and the 
studies were approved by the respective ethics committees 
and institutional review boards. 
The study design has previously been described (Brusasco 
et al 2003; Donohue et al 2002, 2003). In brief, following an 
initial screening to assess eligibility, patients had entered a 
2-week baseline period. Patients who successfully completed 
this phase were randomized into the double-blind portion 
of the study during which they received tiotropium, salme-
terol or placebo for a period of 24 weeks. The drugs were 
administered in a double-dummy design with tiotropium or 
placebo inhalation capsules taken once daily in the morning 
and salmeterol or placebo inhalation aerosol taken twice 
daily (every 12 hours). Clinic visits were scheduled after 2, 
8, 16, and 24 weeks following randomization. 
Study patients
The main inclusion criteria were: age  40 years, a diag-
nosis of COPD with pre-bronchodilator FEV1 at screening International Journal of COPD 2007:2(2)  159
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visit of  60% predicted (calculated according to European 
Commission for Steel and Coal criteria and using predicted 
values from Morris) (Morris et al 1988; Quanier et al 1993) 
and screening FEV1/FVC <0.70. Patients were required to 
have a smoking history of  10 pack-years, and be able 
to perform all study related tests including acceptable 
pulmonary function tests and maintenance of daily diary 
card records. The main exclusion criteria were clinically 
signiﬁ  cant diseases other than COPD which, in the opin-
ion of the investigator, had the potential to impact on the 
patient’s ability to participate in the study, as well as known 
symptomatic prostatic hypertrophy, bladder neck obstruc-
tion, or narrow-angle glaucoma. Additionally, patients with 
a history of asthma, allergic rhinitis, or atopy or who had a 
total blood eosinophil count of  600/μL, patients requiring 
use of supplemental oxygen therapy for more than 1 hour 
per day, a history of life-threatening pulmonary obstruction, 
a history of cystic ﬁ  brosis or bronchiectasis, thoracotomy 
with pulmonary resection, upper respiratory infection in 
the 6 weeks prior to the screening visit or during the run-in 
period were also excluded. 
Treatment with long-acting beta2-adrenergics and anti-
cholinergics, other than study treatment, was discontinued at 
randomization. Patients were allowed to continue treatment 
with stable doses of ICS, theophyllines, and short-acting 
beta2-adrenergic medication as scheduled prior to the study. 
Patients using oral corticosteroids within or 6 weeks prior 
to the study were not included in the analysis.
Efﬁ  cacy evaluations
Pulmonary function testing was conducted prior to the start 
of therapy at 60 and 10 minutes pre-dose at the randomiza-
tion visit and at 30 minutes, 60 minutes, 2, and 3 hours 
post-dosing. As only one study collected spirometry after 
3 hours during clinic visits, only spirometry up to 3 hours 
post-dosing has been considered for the present analysis. 
Pulmonary function tests were repeated at the same time 
intervals after 2, 8, 16, and 24 weeks of therapy. The broncho-
dilator efﬁ  cacy of tiotropium and salmeterol was primarily 
determined by trough FEV1 and FVC response, which was 
deﬁ  ned as the change from baseline at the end of the dosing 
interval, approximately 24 hours post drug administration for 
tiotropium and approximately 12 hours post drug adminis-
tration for salmeterol. Baseline values were the mean of the 
two pre-treatment values measured in the morning of the 
randomization visit prior to administration of the ﬁ  rst dose 
of study medication. Other spirometric parameters analyzed 
included the peak response and AUC0–3 response. 
Patient and investigator administered questionnaires, 
including the St. George’s Respiratory Questionnaire 
(SGRQ) (Jones et al 1991) and Mahler’s Dyspnea Index 
(Mahler et al 1984), were administered at baseline and after 
8, 16, and 24 weeks of therapy. Requirement for as-needed 
salbutamol (albuterol) was monitored throughout the study 
period. Exacerbations were reported as adverse events and 
were deﬁ  ned as a complex of respiratory symptoms (ie, at 
least one of cough, sputum, dyspnea, wheeze, chest dis-
comfort) lasting at least 3 days and usually associated with 
a therapeutic intervention.
Statistical analysis
Data from both studies were pooled for analysis. Patients 
receiving ICS at the time of randomization were separately 
analyzed from those patients without concurrent ICS treat-
ment. For the spirometry measurements, SGRQ total score 
and TDI focal score, analysis of covariance was performed 
with the baseline as a covariate. In order to include the same 
patients at each time point in the 3 hour spirometry sum-
maries, missing values were estimated using other values 
recorded for the patient on that test day. Linear interpolation 
between the two adjacent measurements was used to estimate 
random, middle, and missing spirometry measurements. For 
values at the end of the proﬁ  les that were missing because 
rescue medication was taken, the minimum observed FEV1 
value on that test day was used as the estimate. The last 
available value was used as the estimate for data that were 
missing for other reasons.
For the SGRQ, missing individual questions were 
imputed according to the guidelines established by the 
questionnaire developer. Data from missing SGRQ question-
naires and TDI questions were imputed using last observa-
tion carried forward, unless the patient discontinued due 
to worsening of COPD, in which case the least favorable 
observation was carried forward. The numbers of exacer-
bations over the 6 months period were compared across 
treatment groups using Poisson regression with logarithm 
of exposure as offset and correction for overdispersion as 
recommended by Suissa (2006).
Unless otherwise speciﬁ  ed, data are presented as means 
± standard error. Statistical signiﬁ  cance was considered at 
p < 0.05.
Results
A total 796 of 1207 patients (66%) in the two trials were 
concurrently treated with ICS. Demographic data and 
baseline characteristics for the treatment groups were International Journal of COPD 2007:2(2)  160
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comparable (Tables 1a, b). For patients concurrently 
treated with ICS, mean pre-bronchodilator FEV1 values 
were 39%, 38%, and 40% of predicted in the tiotropium, 
salmeterol, and placebo groups respectively. In general, 
at baseline, the group of patients taking ICS had slightly 
more airway obstruction and poorer health status scores 
than patients not on ICS (p < 0.05). The median daily 
doses and dose ranges of ICS used by the majority of 
these patients for at least 3 months prior to the study are 
shown in Table 2. Fluticasone was the most commonly 
used ICS (approximately 35%–40% in each group) with 
a median daily dose of 1000 μg. The apparent large dose 
ranges observed reflect extreme ICS dosing by one or two 
patients in each treatment group. Twenty-one patients 
from the original data sets, not taking ICS, but receiving 
regular treatment with oral corticosteroids, were excluded 
from the analysis. There were 168 patients concurrently 
taking ICS who were prematurely withdrawn from the 
studies for various reasons. Significantly fewer patients 
taking ICS withdrew in the tiotropium (17%) and sal-
meterol (19%) groups compared with placebo (27%) 
(p < 0.05). Similarly, 68 patients not taking ICS treatment 
did not complete the studies. Of those not taking ICS, 
significantly fewer patients in the tiotropium group (11%) 
withdrew compared with those in the placebo group (23%) 
(p < 0.05). The percentages of patients who withdrew in 
the salmeterol group (18%) were not significantly dif-
ferent from placebo. Overall, adverse events leading to 
discontinuation from the studies occurred in 9%, 16%, 
and 18% of ICS patients, and in 4%, 13%, and 15% of 
patients not using ICS, but these differences were not 
statistically significant. The main adverse event causing 
early withdrawal was worsening of COPD (ICS: 6% tio-
tropium, 12% salmeterol, 12% placebo; non-ICS groups: 
3%, 6%, and 10%, respectively). 
Lung function responses 
Patients treated with ICS
Compared with placebo, patients in both the tiotropium and 
salmeterol groups concurrently treated with ICS achieved sta-
tistically signiﬁ  cant improvements in FEV1 and FVC (trough, 
peak and AUC0–3 hours) throughout the study (p   0.001, 
all comparisons at day 15, 57, 113, and 169) (Figure 1 and 
Table 3a). After 169 days of treatment, the mean + SE im-
provement above placebo in trough FEV1 was 110 + 20 mL 
for tiotropium (p < 0.001) and 80 + 20 mL for salmeterol 
(p < 0.001) (Table 3a). The numerical difference (10–30 mL) 
in trough FEV1 between tiotropium and salmeterol was not 
signiﬁ  cant at 6 months (p = 0.11 tiotropium vs salmeterol). 
Tiotropium was superior in improving trough FVC of pa-
tients using ICS from day 57 to 169 (p < 0.05, tiotropium 
vs salmeterol), and differences between active treatments 
were also statistically signiﬁ  cant in favor of tiotropium for 
peak FEV1 and FVC at the ﬁ  rst dose and at all subsequent 
visits (p < 0.05, tiotropium vs salmeterol). In addition, FEV1 
AUC0–3,  as well as FVC AUC0–3 were consistently statistically 
signiﬁ  cant in favor of tiotropium (p < 0.01, tiotropium vs 
salmeterol) from day 15 to day 169. 
Patients not treated with ICS
In those patients not taking ICS, the patterns of spirometric 
response according to treatment group were similar to those 
observed with the ICS group (Figure 2 and Table 4a). How-
ever, because of the smaller sample size (n = 360) relative 
to the ICS treated group (n = 796), there was insufﬁ  cient 
power to detect statistically signiﬁ  cant differences between 
bronchodilators in this group of patients.
Dyspnea responses
Patients treated with ICS
The mean baseline dyspnea index (BDI) of the patients 
using ICS was 6.2–6.3 in the various treatment groups, 
reflecting a moderate level of dyspnea for all patients 
at the start of the study (Table 1a). Compared with pla-
cebo, ICS patients treated with tiotropium demonstrated 
a clinically and statistically significant improvement in 
TDI focal score throughout the study (p < 0.01 at all time 
points). Patients treated with salmeterol also achieved a 
statistically significant improvement in TDI focal score 
compared with placebo, only after 8 weeks of therapy 
(p < 0.01), but failed to sustain this improvement com-
pared with placebo at 16 and 24 weeks. The difference 
in TDI focal score between the tiotropium and salmeterol 
groups was not statistically significant. However, only in 
patients treated with tiotropium did the improvement in 
TDI reach the minimal clinically important difference of 
1 unit after 169 days of treatment (Table 3a). 
Patients not treated with ICS
In patients not being treated with ICS, the mean improve-
ment in dyspnea as measured by the TDI focal score after 
169 days of treatment was above the minimal clinically 
important difference of 1.0 for both tiotropium and sal-
meterol, but only in patients receiving tiotropium was 
this difference statistically significantly different from 
placebo (Table 4a).International Journal of COPD 2007:2(2)  161
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Health status responses
Patients treated with ICS
Health status, as quantified by the change in SGRQ 
total score after 169 days on treatment, improved sig-
nificantly in patients on ICS treated with tiotropium 
(–3.27 + 1.22   vs placebo; p < 0.01), but not in patients 
receiving salmeterol (–1.12 + 1.21; p > 0.05 vs placebo) 
(Table 4a). Although only patients receiving tiotropium 
experienced a statistically significant improvement in 
SGRQ vs placebo, there was no significant difference in 
SGRQ total score after 6 months between the tiotropium 
and salmeterol groups. When the change in SGRQ total 
score from baseline is considered, only the tiotropium 
group showed an improvement equal to or greater than 
the accepted minimally important clinical difference of 
4 units (Figure 3). 
Patients not treated with ICS
In patients without concurrent ICS treatment, the improvement 
in health status achieved by active study drugs after 169 days of 
treatment did not reach the level of signiﬁ  cance (Table 4a).
Exacerbations
Patients treated with ICS
In patients concurrently treated with ICS there was a trend 
towards reduced exacerbation frequency and number of 
exacerbation days experienced by the tiotropium and salme-
terol groups compared with the placebo group (Table 3b). 
Fewer patients in both the tiotropium and salmeterol groups 
experienced 1 or more exacerbations during the 6 months 
treatment period compared with placebo (40% receiving 
tiotropium or salmeterol, 45% receiving placebo), although 
the differences were not statistically signiﬁ  cant (Table 3b).
Patients not treated with ICS
In patients not receiving concurrent treatment with ICS 
(Table 4b), only tiotropium use was associated with a signiﬁ  cant 
reduction in the number of COPD exacerbations (p < 0.05) and 
in the number of exacerbation days (p < 0.05). The reduction in 
the proportion of patients experiencing an exacerbation of COPD 
approached statistical signiﬁ  cance (p = 0.08). Salmeterol use was 
associated with a signiﬁ  cant numerical reduction in exacerbations 
in this subgroup of patients (p = 0.81).
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Figure 1a Mean trough FEV1 response of active treatment groups above placebo (patients concurrently using ICS).
Figure 1b Mean peak FEV1 response of active treatment groups above placebo (patients concurrently using ICS).International Journal of COPD 2007:2(2)  162
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Safety
A safety summary of the two studies was published previ-
ously (Brusasco et al 2003). Both active treatments were well 
tolerated, with dry mouth the predominant adverse event 
reported in 8% of patients receiving tiotropium (salmeterol 
and placebo 2%, each).
Discussion
A pooled analysis from two studies comparing the long-
acting anticholinergic tiotropium to the long-acting beta2-
adrenergic salmeterol in patients with COPD had previously 
demonstrated a sustained and superior improvement in lung 
function with tiotropium 18 μg once-daily compared to 
salmeterol 50 μg twice-daily regardless of concurrent use 
of ICS (Brusasco et al 2003; Donohue et al 2002, 2003). 
In these two studies, 66% of the patients enrolled had been 
prescribed ICS on a regular basis, providing the opportunity 
to retrospectively analyze the relative efﬁ  cacy of tiotropium 
and salmeterol as a function of the concomitant use of ICS 
in patients with moderately advanced COPD.
In patients with moderate-to-severe COPD, our present 
post-hoc analysis demonstrated superior spirometric 
responses with tiotropium plus ICS compared to salmeterol 
plus ICS. Both long-acting bronchodilators demonstrated an 
Table 1 Patient characteristics at baseline 
(a) Patient characteristics (ICS users) at baseline (mean [SD])
Tiotropium Salmeterol Placebo
N 259 278 259
Mean age (yrs) 64 (8) 64 (8) 65 (8)
Male (%) 79 76 78
Current smokers (%) 41 29 36
Smoking history (pack years) 43 (23) 44 (24) 41 (23)
FEV1 (L) 1.08 (0.37) 1.03 (0.39) 1.09 (0.40)
FEV1 (%predicted)a 39 (12) 38 (13) 40 (13)
FVC (L) 2.53 (0.71) 2.51 (0.78) 2.60 (0.80)
BDI (0–12) 6.3 (2.2) 6.2 (2.3) 6.3 (2.2)
SGRQ (Total) (0–100) 47 (17) 47 (17) 46 (16)
a(Morris 1998). 
(b) Patient characteristics (ICS nonusers) at baseline (mean [SD])
Tiotropium Salmeterol Placebo
N 135 120 135
Mean age (yrs) 64 (8) 65 (8) 64 (9)
Male (%) 74 73 73
Current smokers (%) 46 52 53
Smoking history (pack years) 46 (22) 47 (24) 46 (23)
FEV1 (L) 1.18 (0.41) 1.14 (0.39) 1.07 (0.38)
FEV1 (%predicted)a 43 (13) 42 (12) 40 (13)
FVC (L) 2.63 (0.78) 2.61 (0.73) 2.48 (0.73)
BDI (0–12) 6.7 (2.4) 7.1 (2.2) 6.9 (2.4)
SGRQ (Total) (0–100) 42 (16) 40 (17) 43 (18)
a(Morris 1998). International Journal of COPD 2007:2(2)  163
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improvement in lung function, similar to that observed in 
the original study populations which included patients with 
and without ICS, and it is noteworthy that in the present 
sub-group analysis ICS did not appear to protect against the 
loss of bronchodilator activity over time that was observed 
to occur for salmeterol in the original data set (Donohue 
et al 2002, 2003). The ﬁ  ndings of these two studies comparing 
tiotropium, salmeterol, and placebo are consistent with many 
published studies addressing efﬁ  cacy of bronchodilators in 
COPD and add weight to the modern concept that COPD is 
not necessarily a disease with ﬁ  xed airﬂ  ow obstruction, but 
rather that COPD patients often demonstrate considerable 
bronchodilator response (Nisar et al 1992; Cazzola et al 1999; 
O’Donnell et al 2001, 2004a, b; Tashkin and Cooper 2004). 
Regarding dyspnea and health status in patients concurrently 
using ICS, in the current analysis, only those receiving tio-
tropium showed statistically signiﬁ  cant improvement after 
24 weeks on treatment, and only in the tiotropium group 
did these improvements reach accepted levels of clinical 
importance. 
Table 2  Median daily dose and ranges of ICS in treatment groups for patients concurrently taking ICS
ICS type
and median dose (μg/day)
Tiotropium Salmeterol Placebo
% 
patients
ICS dose 
range (μg/day)
% 
patients
ICS dose range 
(μg/day)
% patients ICS dose range 
(μg/day)
ﬂ  uticasone (1000) 41% 100–1500 36% 220–2000 44% 100–2000
budesonide (800) 33% 160–2400 35% 50–2400 29% 400–1800
beclomethasone (1000) 23% 200–1600 25% 100–2000 22% 100–2250
Note: Percentages do not add up to 100% because of the use of other ICS (ﬂ  unisolide, triamcinolone) by 2%–3% of patients in each treatment group.
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Figure 2a Mean trough FEV1 response of active treatment groups above placebo (patients without ICS treatment).
100
150
200
250
11 55 7 1 1 3 1 6 9
days on treatment
mL Tiotropium
Salmeterol
**
** p<0.001 vs. placebo
+ p<0.05, tiotropium vs. salmeterol
+
** ** ** **
** **
**
**
**
+ +
Figure 2b Mean peak FEV1 response of active treatment groups above placebo (patients without ICS treatment).International Journal of COPD 2007:2(2)  164
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In the original study population there was a relatively 
low number of exacerbations, and in the current subgroup 
analysis only 27% of placebo patients without ICS and 45% 
of placebo patients concurrently treated with ICS experienced 
any exacerbation during the 6-month observation period. 
Although in the original study patients using ICS had expe-
rienced more exacerbations (1.76 exacerbations per patient 
per year in the placebo group) than patients without ICS 
(1.0 exacerbations/patient/year, placebo), because patients 
were not randomized to ICS or non-ICS groups, it should 
be stressed that a comparison of these sub-groups is of lim-
ited value. This apparent difference in exacerbation rates 
according to concurrent ICS use may simply indicate that the 
patients’ physicians had prescribed ICS for those patients they 
felt to have the most unstable COPD. The trend towards a 
reduced number of exacerbations experienced by the patients 
of this subgroup analysis receiving tiotropium (–23%) and 
salmeterol (–17%) did not reach statistical signiﬁ  cance, but 
the magnitude of effect resembled that observed in the original 
study population (Brusasco et al 2003). A recently reported 
prospective trial comparing the addition of combined salme-
terol/ﬂ  uticasone, salmeterol alone, or placebo with COPD 
patients receiving tiotropium was also unable to demonstrate 
a statistically signiﬁ  cant difference in COPD exacerbation 
frequency amongst the treatment groups, but compared with 
placebo, the group treated with tiotropium plus salmeterol/
Table 3 Outcomes in patients using ICS (tiotropium: n = 259; salmeterol: n = 278; placebo: n = 259) 
(a) Treatment response (spirometry, TDI, and SGRQ score) after 169 days
    Tiotropium vs placebo  Salmeterol vs placebo
  Trough  110 + 20**  80 + 20**
FEV1  Peak  220 + 30** †  150 + 30**
 AUC  0–3  190 + 20** †  130 + 20**
  Trough  220 + 40** †  130 + 40**
FVC  Peak  400 + 40** †  220 + 40**
 AUC 0–3  370 + 40** †  230 + 40**
TDI focal score    1.03 + 0.4*  0.57 + 0.4
SGRQ total score    –3.27 + 1.2*  –1.12 + 1.2
*p < 0.05, **p < 0.001 vs placebo; † p < 0.05, tiotropium vs salmeterol.
(b) Treatment response (exacerbations) after 169 days
Tiotropium Salmeterol Placebo
% patients with >1 exacerbation 40% 40% 45%
Exacerbations/patient-year
(% reduction vs placebo)
1.36 (–23%)* 1.46 (–17%)** 1.76
Exacerbation days/patient-year 21.9 26.9 29.3
*p = 0.047, **p = 0.135 vs placebo.
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Figure 3 Improvement in health-related quality of life in active treatment groups compared to baseline SGRQ Total score (patients concurrently using ICS).International Journal of COPD 2007:2(2)  165
Tiotropium or salmeterol plus treatment with ICS for COPD
ﬂ  uticasone had signiﬁ  cantly fewer hospitalizations (Aaron et 
al 2007). Recent prospective studies have observed a positive 
impact of adding an ICS to a long-acting beta2-adrenergic on 
spirometric response, health status, and COPD exacerbations 
(Calverley et al 2003a, 2007; Mahler et al 2002; Szafranski 
et al 2003). The effect of this treatment strategy on mortal-
ity in COPD has also been recently studied, but although an 
absolute reduction in mortality of 2.6% was observed, with 
the combination therapy, this did not achieve statistical sig-
niﬁ  cance (Calverley et al 2007). Prospective trials designed 
to assess the effect of adding an ICS to an anticholinergic 
bronchodilator alone have not been published.
The role of ICS without long-acting bronchodilators in 
the treatment of COPD continues to be a matter of debate. 
Many patients with COPD appear to be steroid-resistant 
based on in vitro studies (Barnes et al 2004, 2005; Culpitt 
et al 2003). However, because clinical trials usually report 
only mean treatment responses, it could be postulated that 
ICS are beneﬁ  cial in COPD, but only for certain sub-sets of 
patients who are not otherwise identiﬁ  ed in clinical trials. 
For example, ICS may have beneﬁ  cial effects by modulating 
inﬂ  ammation driven by eosinophils when present (Pizzichini 
et al 1998; Leigh et al 2006), or mast cells (Hattotuwa et al 
2002). ICS have also been shown to reduce some of the 
systemic markers of inﬂ  ammation in COPD patients (Sin 
et al 2004) and to modulate oxidative damage in COPD 
(Sadowska et al 2005).
The parasympathetic nervous system is felt to be the 
main determinant of airway smooth muscle tone (Douglas 
et al 1979; Cazzola et al 1997; Barnes 2004; Gross 2004) 
and there is evidence that cholinergic tone is increased in 
COPD (Gross and Skorodin 1984; Gross et al 1989). It 
has therefore been suggested that COPD could be more 
effectively treated with anticholinergic drugs than by 
sympathomimetics (Barnes 2004; Gross 2004). Clinical 
data about the co-administration of tiotropium with inhaled 
long-acting beta2-adrenergics is also beginning to emerge 
and it would seem that such additivity does indeed occur 
(Cazzola et al 2004a, b; Tashkin and Cooper 2004; van 
Noord et al 2000, 2005, 2006). 
In summary, the present post-hoc analysis of two 
large-scale trials, comparing the M3 receptor antagonist 
tiotropium and the long-acting beta2-adrenergic salme-
terol to placebo in COPD subgroups with or without con-
current treatment with ICS, confirms that both, tiotropium 
and salmeterol are effective bronchodilators. Clinically 
important endpoints such as dyspnea, health status and 
frequency of exacerbations were also observed and were 
superior with tiotropium compared to salmeterol, regard-
less of concomitant ICS use. While the direct effect of 
ICS on COPD outcomes was not studied in this post-hoc 
analysis, we conclude that concurrent use of ICS neither 
augmented nor impeded the relative efficacy of the two 
bronchodilators tested. 
Table 4 Outcomes in patients not using ICS (tiotropium: n = 135; salmeterol: n = 120; placebo: n = 135)
(a) Treatment response (spirometry, TDI, and SGRQ score) after 169 days
    Tiotropium vs placebo  Salmeterol vs placebo
  Trough  150 + 30*  110 + 30*
FEV1  Peak  220 + 30* †  150 + 30*
 AUC 0-3  220 + 30* †  150 + 30*
  Trough  190 + 50*  130 + 50*
FVC  Peak  300 + 60*  200 + 60*
 AUC 0-3  290 + 50*  200 + 50*
TDI focal score    1.35 + 0.5*  1.02 + 0.55
SGRQ total score    –2.05 + 1.7  –1.66 + 1.8
*p < 0.05 vs placebo; †p < 0.05, tiotropium vs salmeterol.
(b) Treatment response (exacerbations) after 169 days
Tiotropium Salmeterol Placebo
% patients with >1 exacerbation 17% 26% 27%
Number of exacerbations/patient-year
(% reduction vs. placebo)
0.52* (–48%) 0.74 (–36%) 1.00
Exacerbation days/patient-year 8.0* 18.4 16.9
*p < 0.05 vs placebo.International Journal of COPD 2007:2(2)  166
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